A German and UK business-park landlord, an international veterinary-services group, and a global supplier of molten-metal-flow engineering bring three very different exposures to this FTSE 250 analysis. This piece assesses Sirius Real Estate, CVS Group and Vesuvius against verified market data as at 14 September 2026, weighing rental income, structural pet-care growth and industrial cyclicality.

FTSE 250 and UK market context

The FTSE 250 offers exposure to income-producing property, structurally growing healthcare-adjacent services, and cyclical industrial engineering. These three areas respond to different forces — property yields and occupier demand, the resilient growth of pet care, and the industrial and steel cycle — making the index a useful way to assemble a diversified basket of mid-cap exposures.

The month carries a scheduled index event. FTSE Russell announced its September 2026 quarterly review on 2 September, with changes effective from Monday 21 September 2026. Because announced changes take effect only on that date, the 14 September research date used here reflects the pre-review index. None of Sirius Real Estate, CVS Group or Vesuvius appears among the September additions or deletions, so each remains a FTSE 250 constituent through the review.

The macro backdrop supports each differently. Sirius benefits from resilient occupier Demand for flexible Business space in Germany and the UK, with property yields the key valuation variable. CVS Group is exposed to the structurally resilient pet-care market, tempered by a regulatory review of the UK veterinary sector. And Vesuvius is geared to the industrial and steel cycle, which has been subdued but is sensitive to global Manufacturing activity. The recent easing in interest-rate expectations is, at the margin, supportive of the property and cyclical names.

Why these three stocks are attracting attention in September 2026

Sirius Real Estate is an owner and operator of business parks and industrial and office space in Germany and the UK, offering flexible space to a diversified tenant base and combining rental income with active asset management. CVS Group is a leading veterinary-services provider, operating vet practices, laboratories, crematoria and an online pharmacy across the UK and Australia, geared to the structural growth of pet-care spending. Vesuvius is a global leader in molten-metal-flow engineering, supplying ceramics and consumables essential to steel and foundry production.

Their financial profiles differ. As at 14 September 2026, Sirius traded on a single-digit Earnings multiple with a strong Yield and solid earnings growth; CVS Group on a high multiple reflecting its structural-growth positioning and a dip in earnings, with a low yield; and Vesuvius on a mid-20s multiple reflecting depressed cyclical earnings, with a high yield. Together they blend rental income, structural growth and industrial cyclicality.

Sirius Real Estate (SRE) — LSE:SRE

Business model and market position

Sirius Real Estate (LSE:SRE) owns and operates a portfolio of business parks, industrial estates and office space, principally in Germany, complemented by a growing UK presence (through its BizSpace operations). Its model combines ownership of income-producing property with active, hands-on operational management: it lets flexible space to a highly diversified base of small and medium-sized tenants, offers value-added services, and actively manages its Assets to grow occupancy, rents and value. This operationally intensive approach differentiates it from passive landlords and allows it to extract additional value from its estate.

The group classifies within finance/property. Its focus on flexible business space in Germany — Europe's largest economy — and the UK gives it exposure to resilient occupier demand from smaller businesses, while its diversified tenant base reduces reliance on any single occupier. Its active management model, combining rental income with value-add asset management and development, supports both income and Capital growth, and has underpinned a strong track record.

Financial performance and Shareholder returns

As at 14 September 2026, Sirius shares traded at 92.55p, for a Market Capitalisation of approximately £1.46bn. The stock was valued on a low trailing price-to-earnings multiple of around 7.2 times, with trailing Diluted Earnings per Share of roughly 12.9p. Trailing EPS had grown by around 28 per cent year on year on the data reviewed, a strong rate reflecting rental growth and active management. The trailing Dividend Yield stood at an attractive level of around 6 per cent, supported by the rental income stream, making Sirius a compelling combination of income, growth and a low valuation among property names.

Strategy, asset management and RNS watch

Sirius's strategy is to grow rental income and occupancy through active asset management, acquire and improve assets, develop its portfolio, and maintain a strong balance sheet. Investors following the group through the London Stock Exchange's regulatory news service will focus on occupancy, like-for-like rental growth, acquisitions and disposals, net asset value, gearing and the dividend. The direction of property yields and the health of the German and UK economies are the key external drivers, while the group's active management model is central to its ability to grow income and value through the cycle.

Competitive positioning and outlook

Sirius's competitive strengths lie in its operationally intensive, active management model, its scale and expertise in the German business-park market, and its diversified tenant base. Actively managing flexible space — improving occupancy, letting to many smaller tenants, and adding value-added services — requires operational capability that passive landlords lack, and Sirius has built a strong platform and track record in this respect. Its exposure to Germany, Europe's largest economy, and its growing UK presence give it a solid footprint in resilient markets. The combination of a low valuation, a 6 per cent yield, strong earnings growth and an active management model makes Sirius a distinctive property proposition, offering income and growth, though it remains exposed to property yields and the German and UK economic backdrop.

CVS Group (CVSG) — LSE:CVSG

Business model and market position

CVS Group (LSE:CVSG) is one of the largest integrated veterinary-services providers in the UK, and also operates in Australia. Its business spans veterinary practices (small-animal, farm and equine), diagnostic laboratories, pet crematoria, and an online retail and pharmacy operation. This integrated model captures value across the pet-healthcare chain, from primary veterinary care to diagnostics and ancillary services, and benefits from the structural growth of pet-care spending, as pet ownership has risen and owners increasingly treat pets as family members, spending more on their health and wellbeing.

The group classifies within health services. The pet-care market is structurally growing and comparatively resilient, as owners tend to prioritise their pets' health even when budgets tighten. However, a significant sector-specific consideration is the ongoing investigation into the UK veterinary market by the competition authority, which is examining issues such as pricing, competition and transparency in the sector. This regulatory review represents an overhang for CVS Group and other veterinary operators, introducing uncertainty about future practices, pricing and structure that investors must weigh.

Financial performance and shareholder returns

As at 14 September 2026, CVS Group shares traded at 1,295p, for a market capitalisation of approximately £879m. The stock was valued on a high trailing price-to-earnings multiple of around 58 times, with trailing diluted earnings per share of roughly 22.2p; trailing EPS was lower year on year on the data reviewed, so the elevated multiple reflects a combination of a dip in earnings, Investment in the business, and the market's valuation of its structural-growth positioning. The trailing dividend yield was low at around 0.7 per cent, consistent with a business reinvesting for growth. The high multiple and low yield mark CVS as a structural-growth name rather than an income proposition.

Strategy, growth and RNS watch

CVS Group's strategy is to grow its veterinary practices organically and through acquisition, expand its diagnostics and ancillary services, develop its online and pharmacy operations, and grow in Australia. Investors following the group through the London Stock Exchange's regulatory news service will focus on like-for-like Revenue growth, margins, Acquisition activity, the Australian expansion, and — critically — developments in the competition authority's veterinary market investigation. The outcome of that review is the single most important external variable, given its potential to affect pricing, practices and structure across the sector.

Competitive positioning and outlook

CVS Group's competitive strengths lie in its integrated model, its scale in UK veterinary services, and its expertise across the pet-healthcare chain. Integration — combining practices, diagnostics, crematoria and online retail — creates cross-referral opportunities and captures value at multiple stages, while scale supports purchasing power and operational efficiency. The structural growth of pet-care spending provides a supportive long-term backdrop. However, the competition authority's investigation is a material overhang: depending on its outcome, it could affect pricing, transparency requirements and the structure of the sector, introducing uncertainty that the high multiple must be weighed against. CVS Group thus offers exposure to a structurally growing market, but with a significant regulatory question that warrants close attention and that distinguishes its risk profile from other structural-growth names.

Vesuvius (VSVS) — LSE:VSVS

Business model and market position

Vesuvius (LSE:VSVS) is a global leader in molten-metal-flow engineering, supplying advanced ceramics, refractories and consumable products and systems that are essential to the production of steel and to foundry operations. Its products — used to control, contain and shape molten metal — are critical to steelmaking and casting, and are largely consumable, being used up in the production process and requiring regular replacement. This gives Vesuvius recurring demand tied to its customers' production volumes, alongside a strong position in a specialised, technically demanding field.

The group classifies within producer manufacturing and is closely tied to the industrial and steel cycle. Global steel production and foundry activity, which depend on manufacturing, construction and automotive demand, drive its volumes. As a supplier of consumable, mission-critical products to these industries, Vesuvius benefits from recurring demand and from its technical expertise and global footprint, but its earnings are cyclical, rising and falling with industrial activity.

Financial performance and shareholder returns

As at 14 September 2026, Vesuvius shares traded at 369.6p, for a market capitalisation of approximately £903m. The stock was valued on a trailing price-to-earnings multiple of around 24 times, with trailing diluted earnings per share of roughly 15.4p; trailing EPS was substantially lower year on year on the data reviewed, reflecting a subdued industrial and steel cycle, so the elevated multiple is a function of depressed cyclical earnings rather than a rich valuation on mid-cycle profits. The trailing dividend yield stood at an attractive level of around 6.4 per cent, a solid income proposition supported by the group's cash generation even through a weaker part of the cycle.

Strategy, cycle and RNS watch

Vesuvius's strategy is to maintain its technological leadership, grow its share in its markets, manage costs through the cycle, and generate strong Cash Flow to support shareholder returns. Investors following the group through the London Stock Exchange's regulatory news service will focus on Volume trends across steel and foundry markets, margins, cost management, cash generation and the dividend. Global steel production and industrial activity are the dominant external drivers; a recovery in the industrial cycle would provide significant operating leverage, while continued weakness would pressure volumes and earnings.

Competitive positioning and outlook

Vesuvius's competitive strengths lie in its technological leadership, the mission-critical and consumable nature of its products, and its global footprint. Supplying advanced ceramics and systems that control molten metal requires deep technical expertise, and its products are essential to its customers' production, creating close, embedded relationships. The consumable nature of its products provides recurring demand tied to customers' output. Its global scale allows it to serve customers worldwide and to weather regional cyclical variations. The principal variable is the industrial and steel cycle, which has been subdued: earnings are consequently depressed, and the investment case rests substantially on a recovery in industrial activity, which the Operating Leverage in the model would amplify. The high yield provides income while investors await that recovery.

Comparison of the three companies

The trio spans rental income, structural growth and industrial cyclicality. Sirius Real Estate is the income-and-growth property play: an active business-park landlord on a single-digit multiple with a 6 per cent yield and strong earnings growth. CVS Group is the structural-growth play: an integrated veterinary group on a high multiple, geared to resilient pet-care growth but facing a significant regulatory review. Vesuvius is the cyclical-recovery-and-income play: a global industrial engineer whose depressed cyclical earnings produce a high multiple, offering a 6 per cent-plus yield while investors await an industrial recovery.

The right valuation lens differs markedly for each. Sirius should be judged on its rental growth, occupancy and net asset value, where its low multiple and high yield arguably understate the quality of its active management model. CVS Group should be judged on its structural growth and, above all, the outcome of the veterinary market investigation, which its high multiple must be weighed against. Vesuvius should be judged on where it sits in the industrial cycle: its high trailing multiple reflects trough earnings, so the effective valuation on normalised, mid-cycle profits would be considerably lower, and the case rests on a cyclical recovery.

For portfolio construction, the three offer genuinely diversifying exposures. Sirius's returns are driven by German and UK property markets; CVS Group's by pet-care growth and veterinary regulation; and Vesuvius's by the global industrial and steel cycle. These drivers have little in common, so an investor holding all three would spread risk across property, healthcare-adjacent services and industrial engineering. Income-focused investors would gravitate to Sirius and Vesuvius, both offering yields around 6 per cent; those seeking structural growth to CVS Group, provided they are comfortable with the regulatory overhang. All three remain FTSE 250 constituents through the September review.

Key opportunities and potential catalysts

Sirius's catalysts are continued rental and occupancy growth, value-accretive acquisitions and a supportive property-yield environment. CVS Group's opportunities lie in continued pet-care growth, expansion in Australia, and — critically — a benign outcome from the veterinary market investigation. Vesuvius's catalyst is a recovery in the global industrial and steel cycle, which the operating leverage in its model would amplify. An easing interest-rate backdrop would support the property name and, through industrial activity, the cyclical name.

The timing and nature of these catalysts differ in ways that matter for investors. Sirius's drivers are steady and largely within management's control — occupancy and rental growth accrue incrementally through active management — making it the most predictable of the three. CVS Group's key catalyst, the resolution of the veterinary market investigation, is external, binary in character and outside management's control, so its shares may remain range-bound until there is clarity, after which they could re-rate in either direction. Vesuvius's catalyst, an industrial-cycle recovery, is macroeconomic and gradual, dependent on global manufacturing and steel demand; it cannot be willed into being, but when it arrives the operating leverage in the model can drive a rapid improvement in earnings. Understanding not just what could drive each stock but when and how those drivers might materialise is essential to setting realistic expectations for each.

Key risks

Sirius is exposed to property yields, the German and UK economies, and the operational intensity of active management. CVS Group faces the significant uncertainty of the veterinary market investigation, alongside competition and the execution of its acquisition strategy; its high multiple offers little room for disappointment. Vesuvius is exposed to the industrial and steel cycle, which drives its volumes and earnings, and to input and energy costs. Broad macroeconomic conditions bear on all three, with Vesuvius most cyclically exposed, Sirius most sensitive to interest rates, and CVS Group most exposed to regulatory outcomes.

What investors may watch through the remainder of September 2026

Through late September, the FTSE reshuffle effective 21 September 2026 will influence mid-cap flows generally, though none of these companies is directly affected. Company-specific attention will focus on Sirius's rental and occupancy trends, any developments in the veterinary market investigation affecting CVS Group, and Vesuvius's volume and Margin commentary, all via the London Stock Exchange's regulatory news service. Prices and valuations quoted here are as at 14 September 2026 and should be re-verified against live data before any decision.

Conclusion

Sirius Real Estate, CVS Group and Vesuvius illustrate three distinct propositions within the FTSE 250: an income-and-growth business-park landlord, a structurally growing veterinary group facing a regulatory review, and a cyclical industrial engineer geared to an eventual recovery. As at 14 September 2026 each offered a different balance of income, growth and cyclicality, and each remains in the index through the September review. The appropriate choice depends on whether an investor prioritises property income-and-growth, structural pet-care growth or industrial-cycle recovery — and on their tolerance for the specific risks each entails, including the regulatory overhang facing CVS Group.